Rad21: A Protein Regulator of Male Characteristics and Cancer Development

Target Name: RAD21

NCBI ID: G5885

RAD21

Rad21: A Protein Regulator of Male Characteristics and Cancer Development

Rad21 (SCC1) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. Its name comes from its position in the SCC gene cluster, which encodes a family of proteins that play a role in cell signaling.

Rad21 is a 21-kDa protein that is expressed in the brain, pancreas, and gastrointestinal tract. It is highly expressed in the liver and moderately expressed in the kidneys and spleen. Rad21 is predominantly localized to the endoplasmic reticulum (ER) and nuclear envelope, and is also found in the cytoplasm.

Rad21 functions as a negative regulator of the androgen receptor (AR), which is a key transcription factor that regulates the expression of genes involved in male characteristics. The AR is a nuclear receptor that is activated by androgens, such as testosterone. When androgens bind to the AR, they cause the receptor to transactivate, leading to the transcription of genes involved in male characteristics.

Rad21 is a critical regulator of the AR, and its function in this role is essential for the development and maintenance of male characteristics. In addition to its role in regulating the AR, Rad21 is also involved in the regulation of cell signaling pathways that are important for various cellular processes, including cell growth, apoptosis, and inflammation.

Rad21 has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of Rad21 are associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer that arises from the ducts that carry bile from the liver to the pancreas.

In addition to its involvement in cancer, Rad21 is also implicated in the development of other diseases. For example, Rad21 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that the levels of Rad21 are elevated in the brains of individuals with these conditions, and that reducing Rad21 levels may be a potential therapeutic approach.

Furthermore, Rad21 is also involved in the regulation of insulin sensitivity, which is an important factor in the development of type 2 diabetes. Insulin sensitivity is regulated by various signaling pathways, including those involving the AR. Therefore, changes in Rad21 levels may be involved in the development and progression of type 2 diabetes.

In conclusion, Rad21 is a protein that is involved in various cellular processes that are important for the development and maintenance of human characteristics. Its role in the regulation of the AR and cell signaling pathways is essential for the development and maintenance of male characteristics. Rad21 is also implicated in the development of various diseases, including cancer, neurodegenerative diseases, and type 2 diabetes. Therefore, Rad21 may be a promising drug target or biomarker for the development of new therapies.

Protein Name: RAD21 Cohesin Complex Component

Functions: As a member of the cohesin complex, involved in sister chromatid cohesion from the time of DNA replication in S phase to their segregation in mitosis, a function that is essential for proper chromosome segregation, post-replicative DNA repair, and the prevention of inappropriate recombination between repetitive regions (PubMed:11509732). The cohesin complex may also play a role in spindle pole assembly during mitosis (PubMed:11590136). In interphase, cohesins may function in the control of gene expression by binding to numerous sites within the genome (By similarity). May control RUNX1 gene expression (Probable). Binds to and represses APOB gene promoter (PubMed:25575569). May play a role in embryonic gut development, possibly through the regulation of enteric neuron development (By similarity)

The "RAD21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets